The number of CD16+ cells is positively correlated with liver damage and the progression of liver fibrosis in patients with hepatitis B. For patients with pancreatic cancer, CD16+ monocytes can activate pancreatic stellate cells and promote the formation of local fibrosis in pancreatic cancer. This evidence concerns the gene FCGR3A and Hepatic fibrosis.